Daily Pill Can Double Survival Time for World’s Deadliest Cancer, Trial Shows

Why It Matters

Doubling overall survival could dramatically improve outcomes for a cancer with a five‑year mortality rate above 90%, prompting rapid adoption and further investment in KRAS‑targeted therapies. The results also signal a new therapeutic class that may be applicable to other KRAS‑driven malignancies.

Key Takeaways

• Daraxonrasib doubled median overall survival to 13.2 months vs 6.6 months.
• Trial enrolled 500 advanced pancreatic cancer patients across multiple sites.
• Drug targets KRAS, the most common driver mutation in PDAC.
• Fewer adverse events reported compared with standard chemotherapy.
• Success may accelerate KRAS inhibitor development for other solid tumors.

Pulse Analysis

Pancreatic ductal adenocarcinoma remains the most lethal solid tumor in the United States, with a five‑year survival rate hovering around 10 percent. The disease’s aggressiveness stems from late‑stage diagnosis and a paucity of effective systemic therapies. KRAS mutations drive over 90 percent of cases, yet attempts to drug this protein have historically failed due to its smooth surface and high affinity for GTP. Recent advances in molecular glue technology have finally yielded compounds that can lock KRAS in an inactive state, opening a therapeutic window that daraxonrasib exploits.

The ASCO‑presented trial enrolled 500 patients with metastatic disease and compared daily daraxonrasib against physician‑chosen chemotherapy. Participants receiving the oral agent achieved a median overall survival of 13.2 months, effectively doubling the control arm’s 6.6‑month benchmark. Importantly, the safety profile was more favorable, with lower rates of neutropenia, nausea, and fatigue, suggesting that patients could maintain quality of life while gaining additional months. The drug’s multi‑selective Ras(On) inhibition allows it to suppress a broad spectrum of KRAS variants, addressing the heterogeneity that has hampered earlier inhibitors.

Beyond pancreatic cancer, the success of daraxonrasib revitalizes the broader KRAS inhibitor pipeline. Ongoing studies are evaluating similar molecules in KRAS‑mutant lung and colorectal cancers, where the unmet need is equally pressing. Regulatory agencies are likely to prioritize expedited review pathways given the high‑mortality context, while insurers may negotiate pricing based on the survival benefit. If the drug secures approval, it could catalyze a wave of investment in Ras‑targeted platforms, reshaping the oncology landscape for multiple tumor types.